Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470249 | 0.90 | MME (0.41) | GAAF2F10PRSS1CTSK | |
| SCHEMBL24403220 | 0.90 | MME (0.41) | GAAF2F10PRSS1CTSK | |
| SCHEMBL13928417 | 0.90 | MME (0.41) | GAAF2F10PRSS1CTSK | |
| SCHEMBL29866112 | 0.86 | F2 (0.35) | GAAF2F10PRSS1CTSK | |
| SCHEMBL6564073 | 0.84 | GAA (0.42) | GAAF2F10PRSS1CTSK | |
| SCHEMBL29866132 | 0.82 | GAA (0.38) | GAAF2F10PRSS1MEN1 | |
| SCHEMBL10264443 | 0.81 | GAA (0.46) | GAAF2F10PRSS1CTSK | |
| SCHEMBL325216 | 0.81 | GAA (0.46) | GAAF2F10PRSS1CTSK | |
| SCHEMBL22648647 | 0.81 | GAA (0.38) | GAAF2F10PRSS1KMT2A | |
| SCHEMBL5936027 | 0.81 | GAA (0.39) | GAAF2F10PRSS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324800-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. | 2022-10-13 | — | — | US | disclosed |
| WO-2022212707-A1 | SARS-3CL PROTEASE INHIBITORS | Primmune Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324800-A1 | SARS-3CL PROTEASE INHIBITORS | ACE, ACE2, SARS1 | GAA 355/4885F2 925/4885F10 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.